Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers.

Bose N, Ottoson NR, Qiu X, Harrison B, Lowe JR, Uhlik MT, Rathmann BT, Kangas TO, Jordan LR, Ertelt KE, Jonas AB, Walsh RM, Chan ASH, Fulton RB, Leonardo SM, Fraser KA, Gorden KB, Matson MA, Graff JR, Huhn RD.

J Immunol. 2019 May 15;202(10):2945-2956. doi: 10.4049/jimmunol.1801533. Epub 2019 Apr 15.


A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.

Thomas M, Sadjadian P, Kollmeier J, Lowe J, Mattson P, Trout JR, Gargano M, Patchen ML, Walsh R, Beliveau M, Marier JF, Bose N, Gorden K, Schneller F 3rd.

Invest New Drugs. 2017 Jun;35(3):345-358. doi: 10.1007/s10637-017-0450-3. Epub 2017 Mar 16.


Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation.

Chan AS, Jonas AB, Qiu X, Ottoson NR, Walsh RM, Gorden KB, Harrison B, Maimonis PJ, Leonardo SM, Ertelt KE, Danielson ME, Michel KS, Nelson M, Graff JR, Patchen ML, Bose N.

PLoS One. 2016 Nov 3;11(11):e0165909. doi: 10.1371/journal.pone.0165909. eCollection 2016.


Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent.

Bose N, Chan AS, Guerrero F, Maristany CM, Qiu X, Walsh RM, Ertelt KE, Jonas AB, Gorden KB, Dudney CM, Wurst LR, Danielson ME, Elmasry N, Magee AS, Patchen ML, Vasilakos JP.

Front Immunol. 2013 Aug 12;4:230. doi: 10.3389/fimmu.2013.00230. eCollection 2013.


Low serum vitamin D concentrations in patients with schizophrenia.

Itzhaky D, Amital D, Gorden K, Bogomolni A, Arnson Y, Amital H.

Isr Med Assoc J. 2012 Feb;14(2):88-92.


EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC.

Gorden KJ, Mesbah P, Kolesar JM.

J Oncol Pharm Pract. 2012 Jun;18(2):245-9. doi: 10.1177/1078155211408373. Epub 2011 Jul 6. Review.


Impact of early adolescent psychiatric and personality disorder on long-term physical health: a 20-year longitudinal follow-up study.

Chen H, Cohen P, Crawford TN, Kasen S, Guan B, Gorden K.

Psychol Med. 2009 May;39(5):865-74. doi: 10.1017/S0033291708004182. Epub 2008 Sep 8.


Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.

Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS.

J Immunol. 2006 Dec 1;177(11):8164-70.


Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.

Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS.

J Immunol. 2006 Nov 15;177(10):6584-7.


Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS.

Int Immunol. 2006 Jul;18(7):1115-26. Epub 2006 May 25.


Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.

Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B.

J Exp Med. 2006 Feb 20;203(2):413-24. Epub 2006 Feb 6.


Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP.

J Immunol. 2005 Feb 1;174(3):1259-68.


Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP.

Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.


The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.

Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR.

Blood. 1997 May 1;89(9):3477-85.


B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.

Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray GS, Orchard PJ, Blazar BR.

Cancer Gene Ther. 1995 Mar;2(1):39-46.


Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors.

Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR.

J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):81-90.


The isocitrate dehydrogenase phosphorylation cycle. Identification of the primary rate-limiting step.

Stueland CS, Gorden K, LaPorte DC.

J Biol Chem. 1988 Dec 25;263(36):19475-9.

Supplemental Content

Loading ...
Support Center